Akinyemi Oni-Orisan, PharmD, PhD

Associate Professor
Department of Clinical Pharmacy
Oni-Orisan
Anna Wu
[email protected]
Phone: +1 415 502-7551
Fax: +1 415 476-6632
490 Illinois Street, Rm 33N
UCSF Box 0613
San Francisco, CA 94158
United States

Links

Oni-Orisan Lab UCSF Profiles

Affiliations

Education programs

PharmD Degree Program
Pharmaceutical Sciences and Pharmacogenomics (PSPG) PhD Program
Clinical Pharmacology and Therapeutics (CPT) Postdoctoral Training Program

UCSF centers, institutes, and research programs

Cardiovascular Research Institute (CVRI)
Multiethnic Health Equity Research Center (MERC)

School committees and service

Anti-Racist Curriculum Task Force, 2021, University of California San Francisco
DEI-AR Genetics Education Workgroup, 2020, University of California San Francisco

Department committees and service

Diversity Leader, 2021-present, Department of Clinical Pharmacy
DEI-AR Committee, 2022-present, Department of Clinical Pharmacy

What I do

My lab conducts computational research investigating therapies for cardiovascular disease using observational data from electronic health records. I also teach pharmacy students in the Discovery Projects research program including leading the Health Disparities Discovery Group and serving as a primary mentor for students in the Pharmacogenomics Discovery Group.

Departmental research area

clinical research

My research expertise

pharmacogenomics, pharmacoepidemiology, clinical research in historically minoritized groups, electronic health records

Clinical expertise

cardiovascular disease risk reduction, lipid management

Professional background

Degrees

PhD, Pharmacotherapy and Experimental Therapeutics, University of North Carolina
PharmD, University of Michigan
BS, Biology, University of Michigan

Training and professional development

Diversity, Equity, and Inclusion Champion Training, University of California San Francisco, 2022
Career Conversations, University of California San Francisco, 2022
Tea House Series Facilitator Training, University of California San Francisco, 2021

Biography

The long-term research goal of Dr. Oni-Orisan’s lab is to improve pharmacological regimens for the prevention and treatment of cardiovascular disease in diverse populations through precision medicine. To accomplish this objective, his group combines computational approaches in pharmacogenomics and pharmacoepidemiology using electronic health record-linked biobanks. His lab is currently funded to investigate genetic determinants of efficacy and safety for statin therapy in diverse populations.

Dr. Oni-Orisan teaches and mentors pharmacy students in the Discovery Projects research program including leading the inaugural Health Disparities Discovery Group.

Dr. Oni-Orisan serves as Diversity Leader for the Department of Clinical Pharmacy to champion diversity, equity and inclusion (DEI) efforts in the department.

Research keywords

  • pharmacogenomics
  • health disparities
  • Cardiovascular drugs
  • Cytochrome P-450 CYP2D6
  • Cardiovascular Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Muscular Diseases
  • Eicosanoids
  • Epoxide Hydrolases
  • precision medicine
  • health equity
  • Cholesterol, LDL
  • pharmacogenetics
  • Patient Acuity
  • Drug-Related Side Effects and Adverse Reactions
  • Bilirubin
  • Cytochrome P-450 Enzyme System
  • Lovastatin

Publications

Smith DM, Douglas MP, Aquilante CL, Deverka PA, Devine B, Dunnenberger HM, Empey PE, Hertz DL, Monte AA, Moyer AM, Patel JN, Pratt VM, Saulsberry L, Scott SA, Voora D, Woodahl EL, Whirl-Carrillo M, Oni-Orisan A, Pharmacogenomics Global Research Network (PGRN) Publications Committee. Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges. Clin Pharmacol Ther. 2025 Jun 04.
Ferguson EL, Zimmerman SC, Jiang C, Choi M, Meyers TJ, Hoffmann TJ, Gilsanz P, Wang J, Oni-Orisan A, Whitmer RA, Risch N, Krauss RM, Patel CJ, Schaefer CA, Glymour MM. Uncertainty in the estimated effects of statin initiation on risk of dementia: using a multiverse analysis to assess sources of variability. Eur J Epidemiol. 2025 May 03.
Ferguson EL, Hoffmann TJ, Oni-Orisan A, Risch N, Krauss RM, Schaefer CA, Glymour M. Response to "Comment on 'Independent associations of high-density lipoprotein cholesterol and triglyceride levels with Alzheimer's disease and related dementias' ". Alzheimers Dement. 2025 May; 21(5):e70234.
Sharma S, Gerhart J, Minichmayr IK, Strydom N, Maglalang PD, Liao M, Long T, Tang Girdwood S, Oni-Orisan A, Nakhla K, Li D. Empowering Early-Career Scientists: Opportunities Through ASCPT Programs, Networks, and Communities. Clin Pharmacol Ther. 2025 Jun; 117(6):1495-1498.
Kuang YL, Locatelli CAA, Qin Y, Zhang Y, Theusch E, Muñoz-Howell A, Sanchez G, Lu M, Nguyen MA, Yalamanchili T, Wang X, Nalula G, Mattis AN, Oni-Orisan A, Iribarren C, Krauss RM, Mulvihill EE, Medina MW. MIR192 Upregulates GLP-1 Receptor and Improves Statin-Induced Impairment of Insulin Secretion. bioRxiv. 2025 Mar 19.
Haldar T, Kvale M, Yang J, Douglas MP, Coyote-Maetas W, Kachuri L, Witte JS, Iribarren C, Medina MW, Krauss RM, Yee SW, Oni-Orisan A. SLCO1B1 Functional Variants, Bilirubin, Statin-Induced Myotoxicity, and Recent Sub-Saharan African Ancestry: A Precision Medicine Health Equity Study. Clin Pharmacol Ther. 2025 Jun; 117(6):1696-1705.
Choi M, Zimmerman SC, Jiang C, Wang J, Swinnerton K, Hoffmann TJ, Oni-Orisan A, Ferguson EL, Meyers T, Choudhary V, Whitmer RA, Risch N, Krauss RM, Schaefer CM, Glymour MM, Gilsanz P. Sociodemographic modifiers of effects of statin initiation on dementia incidence: An emulated trial design in a large health care member population with 10+ years of follow-up. Alzheimers Dement. 2025 Mar; 21(3):e14627.
Ferguson EL, Zimmerman SC, Jiang C, Choi M, Meyers TJ, Hoffmann TJ, Gilsanz P, Oni-Orisan A, Wang J, Whitmer RA, Risch N, Krauss RM, Schaefer CA, Glymour MM. Independent associations of high-density lipoprotein cholesterol and triglyceride levels with Alzheimer's disease and related dementias. Alzheimers Dement. 2025 Feb; 21(2):e14575.
Popejoy AB, Ritter DI, Azzariti D, Berg JS, Bulkley JE, Cho M, Gonzaga-Jauregui C, Klein TE, Martschenko DO, Oni-Orisan A, Ramos EM, Rehm HL, Riggs ER, Wright MW, Yudell M, Plon SE, Morales J. Design and implementation of an action plan for justice, equity, diversity, and inclusion within the Clinical Genome Resource. Am J Hum Genet. 2025 Feb 06; 112(2):215-223.
Sadowski M, Thompson M, Mefford J, Haldar T, Oni-Orisan A, Border R, Pazokitoroudi A, Cai N, Ayroles JF, Sankararaman S, Dahl AW, Zaitlen N. Characterizing the genetic architecture of drug response using gene-context interaction methods. Cell Genom. 2024 Dec 11; 4(12):100722.
Zhang P, Munier JJ, Wiese CB, Vergnes L, Link JC, Abbasi F, Ronquillo E, Scheker K, Muñoz A, Kuang YL, Theusch E, Lu M, Sanchez G, Oni-Orisan A, Iribarren C, McPhaul MJ, Nomura DK, Knowles JW, Krauss RM, Medina MW, Reue K. X chromosome dosage drives statin-induced dysglycemia and mitochondrial dysfunction. Nat Commun. 2024 Jul 02; 15(1):5571.
Chong S, Huynh B, Wong S, Woldeyesus T, Faulks M, El-Amin K, Thibeaux J, Lewis J, Harlin R, Carter M, Shatara R, Zhou C, Oni-Orisan A. Preferences and Perspectives of Black Male Barbershop Patrons on Receiving Health Care in Nontraditional Settings. Health Equity. 2023; 7(1):835-842.
Yee SW, Haldar T, Kvale M, Yang J, Douglas MP, Oni-Orisan A. SLCO1B1 functional variants and statin-induced myopathy in people with recent genealogical ancestors from Africa: a population-based real-world study. medRxiv. 2023 Dec 03.
Ferguson EL, Zimmerman SC, Jiang C, Choi M, Swinnerton K, Choudhary V, Meyers TJ, Hoffmann TJ, Gilsanz P, Oni-Orisan A, Whitmer RA, Risch N, Krauss RM, Schaefer CA, Glymour MM. Low- and High-Density Lipoprotein Cholesterol and Dementia Risk Over 17 Years of Follow-up Among Members of a Large Health Care Plan. Neurology. 2023 Nov 21; 101(21):e2172-e2184.
Zimmerman SC, Ferguson EL, Choudhary V, Ranatunga DK, Oni-Orisan A, Hayes-Larson E, Duarte Folle A, Mayeda ER, Whitmer RA, Gilsanz P, Power MC, Schaefer C, Glymour MM, Ackley SF. Metformin Cessation and Dementia Incidence. JAMA Netw Open. 2023 10 02; 6(10):e2339723.
Oni-Orisan A, Tuteja S, Hoffecker G, Smith DM, Castrichini M, Crews KR, Murphy WA, Nguyen NHK, Huang Y, Lteif C, Friede KA, Tantisira K, Aminkeng F, Voora D, Cavallari LH, Whirl-Carrillo M, Duarte JD, Luzum JA, Pharmacogenomics Global Research Network (PGRN) Publications Committee. An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers. Clin Pharmacol Ther. 2023 08; 114(2):275-287.
Kachuri L, Mak ACY, Hu D, Eng C, Huntsman S, Elhawary JR, Gupta N, Gabriel S, Xiao S, Keys KL, Oni-Orisan A, Rodríguez-Santana JR, LeNoir MA, Borrell LN, Zaitlen NA, Williams LK, Gignoux CR, Burchard EG, Ziv E. Gene expression in African Americans, Puerto Ricans and Mexican Americans reveals ancestry-specific patterns of genetic architecture. Nat Genet. 2023 06; 55(6):952-963.
Oni-Orisan A, Lu M, Peng JA, Krauss RM, Iribarren C, Medina MW. Development and application of an algorithm for statin-induced myopathy based on electronic health record-derived structured elements. medRxiv. 2023 Apr 25.
Kehinde O, Ramsey LB, Gaedigk A, Oni-Orisan A. Advancing CYP2D6 Pharmacogenetics through a Pharmacoequity Lens. Clin Pharmacol Ther. 2023 07; 114(1):69-76.
Brown K, Etrouth S, Jayachandran P, Moore J, Oni-Orisan A, Vasist L, Zheng S, Zhou Z, Dresser M. Diversity in Clinical Pharmacology: A Call to Action. Clin Pharmacol Ther. 2023 03; 113(3):483-485.
Hoffmann TJ, Lu M, Oni-Orisan A, Lee C, Risch N, Iribarren C. A large genome-wide association study of QT interval length utilizing electronic health records. Genetics. 2022 11 30; 222(4).
Oni-Orisan A, Haldar T, Cayabyab MAS, Ranatunga DK, Hoffmann TJ, Iribarren C, Krauss RM, Risch N. Polygenic Risk Score and Statin Relative Risk Reduction for Primary Prevention of Myocardial Infarction in a Real-World Population. Clin Pharmacol Ther. 2022 11; 112(5):1070-1078.
Haldar T, Oni-Orisan A, Hoffmann TJ, Schaefer C, Iribarren C, Krauss RM, Medina MW, Risch N. Modest effect of statins on fasting glucose in a longitudinal electronic health record based cohort. Cardiovasc Diabetol. 2022 07 14; 21(1):132.
Wang EY, Breyer BN, Lee AW, Rios N, Oni-Orisan A, Steinman MA, Sim I, Kenfield SA, Bauer SR. Perceptions of Older Men Using a Mobile Health App to Monitor Lower Urinary Tract Symptoms and Tamsulosin Side Effects: Mixed Methods Study. JMIR Hum Factors. 2021 Dec 24; 8(4):e30767.
Lee AW, Kenfield SA, Wang EY, Enriquez A, Oni-Orisan A, Steinman MA, Sim I, Breyer BN, Bauer SR. Tracking Lower Urinary Tract Symptoms and Tamsulosin Side Effects Among Older Men Using a Mobile App (PERSONAL): Feasibility and Usability Study. JMIR Form Res. 2021 Dec 10; 5(12):e30762.
Mantri N, Lu M, Zaroff JG, Risch N, Hoffmann T, Oni-Orisan A, Lee C, Jorgenson E, Iribarren C. QT Interval Dynamics and Cardiovascular Outcomes: A Cohort Study in an Integrated Health Care Delivery System. J Am Heart Assoc. 2021 10 05; 10(19):e018513.
Mantri N, Lu M, Zaroff JG, Risch N, Hoffmann T, Oni-Orisan A, Lee C, Iribarren C. Torsade de pointes: A nested case-control study in an integrated healthcare delivery system. Ann Noninvasive Electrocardiol. 2022 01; 27(1):e12888.
Giacomini KM, Karnes JH, Crews KR, Monte AA, Murphy WA, Oni-Orisan A, Ramsey LB, Yang JJ, Whirl-Carrillo M. Advancing Precision Medicine Through the New Pharmacogenomics Global Research Network. Clin Pharmacol Ther. 2021 09; 110(3):559-562.
Lu B, Sun L, Seraydarian M, Hoffmann TJ, Medina MW, Risch N, Iribarren C, Krauss RM, Oni-Orisan A. Effect of SLCO1B1 T521C on Statin-Related Myotoxicity With Use of Lovastatin and Atorvastatin. Clin Pharmacol Ther. 2021 09; 110(3):733-740.
Oni-Orisan A, Srinivas N, Mehta K, Das JL, Nguyen TT, Tison GH, Bauer SR, Burian M, Funk RS, Graham RA, Biomarkers and Translational Tools Community Working Group of the American Society for Clinical Phar. Leveraging innovative technology to generate drug response phenotypes for the advancement of biomarker-driven precision dosing. Clin Transl Sci. 2021 05; 14(3):784-790.
Oni-Orisan A, Mavura Y, Banda Y, Thornton TA, Sebro R. Embracing Genetic Diversity to Improve Black Health. N Engl J Med. 2021 Mar 25; 384(12):1163-1167.
Bauer SR, Breyer BN, Oni-Orisan A, Steinman MA, Sim I, McCulloch CE, Kenfield SA. PERSONAL: Feasibility Study Protocol for Placebo-Controlled, Randomized n-of-1 Trials of Tamsulosin for Lower Urinary Tract Symptoms. Front Digit Health. 2020; 2:7.
Oni-Orisan A, Haldar T, Ranatunga DK, Medina MW, Schaefer C, Krauss RM, Iribarren C, Risch N, Hoffmann TJ. The impact of adjusting for baseline in pharmacogenomic genome-wide association studies of quantitative change. NPJ Genom Med. 2020; 5:1.
Fohner AE, Ranatunga DK, Thai KK, Lawson BL, Risch N, Oni-Orisan A, Jelalian AT, Rettie AE, Liu VX, Schaefer CA. Assessing the clinical impact of CYP2C9 pharmacogenetic variation on phenytoin prescribing practice and patient response in an integrated health system. Pharmacogenet Genomics. 2019 10; 29(8):192-199.
Oni-Orisan A, Hoffmann TJ, Ranatunga D, Medina MW, Jorgenson E, Schaefer C, Krauss RM, Iribarren C, Risch N. Characterization of Statin Low-Density Lipoprotein Cholesterol Dose-Response Using Electronic Health Records in a Large Population-Based Cohort. Circ Genom Precis Med. 2018 09; 11(9):e002043.
Oni-Orisan A, Cresci S, Jones PG, Theken KN, Spertus JA, Lee CR. Association between the EPHX2 p.Lys55Arg polymorphism and prognosis following an acute coronary syndrome. Prostaglandins Other Lipid Mediat. 2018 09; 138:15-22.
Dong OM, Li A, Suzuki O, Oni-Orisan A, Gonzalez R, Stouffer GA, Lee CR, Wiltshire T. Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients. Pharmacogenomics. 2018 06 01; 19(9):771-782.
Akinyemi Oni-Orisan, Thomas Hoffmann, Marisa Medina, Eric Jorgenson, Catherine Schaefer, Ronald Krauss, Carlos Iribarren, Neil Risch. Validation of Electronic Health Records for the Assessment of Statin Dosing In Research. Journal of Clinical Lipidology. 2017 May 1; 11(3):836-837.
Bai X, Mangum KD, Dee RA, Stouffer GA, Lee CR, Oni-Orisan A, Patterson C, Schisler JC, Viera AJ, Taylor JM, Mack CP. Blood pressure-associated polymorphism controls ARHGAP42 expression via serum response factor DNA binding. J Clin Invest. 2017 Feb 01; 127(2):670-680.
Oni-Orisan A, Edin ML, Lee JA, Wells MA, Christensen ES, Vendrov KC, Lih FB, Tomer KB, Bai X, Taylor JM, Stouffer GA, Zeldin DC, Lee CR. Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans: a targeted metabolomics study. J Lipid Res. 2016 Jan; 57(1):109-19.
Oni-Orisan A, Lanfear DE. Pharmacogenomics in heart failure: where are we now and how can we reach clinical application? Cardiol Rev. 2014 Sep-Oct; 22(5):193-8.
Oni-Orisan A, Alsaleh N, Lee CR, Seubert JM. Epoxyeicosatrienoic acids and cardioprotection: the road to translation. J Mol Cell Cardiol. 2014 Sep; 74:199-208.
Cicci JD, Reed BN, McNeely EB, Oni-Orisan A, Patterson JH, Rodgers JE. Acute decompensated heart failure: evolving literature and implications for future practice. Pharmacotherapy. 2014; 34(4):373-88.
Oni-Orisan A, Deng Y, Schuck RN, Theken KN, Edin ML, Lih FB, Molnar K, DeGraff L, Tomer KB, Zeldin DC, Lee CR. Dual modulation of cyclooxygenase and CYP epoxygenase metabolism and acute vascular inflammation in mice. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug; 104-105:67-73.
Theken KN, Deng Y, Schuck RN, Oni-Orisan A, Miller TM, Kannon MA, Poloyac SM, Lee CR. Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism. Am J Physiol Endocrinol Metab. 2012 Mar 01; 302(5):E500-9.